Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Nepal protests
  • Nepal Protests Live
  • Vice-presidential elections
  • iPhone 17
  • IND vs PAK cricket
  • Israel-Hamas war
fp-logo
Sun Pharma's MD Dilip Shanghvi says shareholders not disadvantaged in transactions with Aditya Medisales
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • Business
  • Sun Pharma's MD Dilip Shanghvi says shareholders not disadvantaged in transactions with Aditya Medisales

Sun Pharma's MD Dilip Shanghvi says shareholders not disadvantaged in transactions with Aditya Medisales

Press Trust of India • February 13, 2019, 14:25:08 IST
Whatsapp Facebook Twitter

Drug major Sun Pharmaceutical Industries has said its shareholders were not disadvantaged in transactions with Aditya Medisales and the company has responded to queries from market regulator Sebi

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
Sun Pharma's MD Dilip Shanghvi says shareholders not disadvantaged in transactions with Aditya Medisales

New Delhi: Drug major Sun Pharmaceutical Industries has said its shareholders were not disadvantaged in transactions with Aditya Medisales and the company has responded to queries from market regulator Sebi. Aditya Medisales has been the domestic distributor of the drug major but the company has said it would be replaced by a subsidiary of Sun Pharma. Aditya Medisales is reported to have had transactions of over Rs 5,800 crore with a real estate firm, Suraksha Realty that is promoted by Sudhir Valia, who is the brother-in-law of Sun Pharma promoter Dilip Sanghvi. Valia is also an executive director in the pharmaceutical major. “I would like to reassure investors that at no point of time Sun Pharma’s shareholders have been disadvantaged in transactions with Aditya Medisales,” Sun Pharma MD Dilip Shanghvi said while addressing the conference call on Tuesday. [caption id=“attachment_2204748” align=“alignleft” width=“380”]A file photo of Dilip Shanghvi. Reuters A file photo of Dilip Shanghvi. Reuters[/caption] Shanghvi was responding to the concern raised by some investors whether Aditya Medisales has benefited in the past at the cost of Sun Pharma’s minority shareholders. He further said, Sun Pharma has responded to two queries raised by market regulator Sebi regarding the 2004 foreign currency convertible bond (FCCB) issuance by the company and transactions with Aditya Medisales. On the response by the company to the queries raised by Securities and Exchange Board of India (Sebi), Shanghvi said: “While we do not have access to the whistleblower documents, we have received an information request from SEBI related to our 2004 FCCB issuance and also for our transactions with Aditya Medisales. “We have responded to these queries. Beyond this, we do not have any update to share.” Sun Pharmaceutical Industries has reported a nearly four-fold jump in its consolidated net profit at Rs 1,241.85 crore for the quarter ended on 31 December, 2018. The company had posted a net profit of Rs 321.57 crore for the corresponding period of the previous fiscal hit by one-time deferred tax adjustment. “Net profit for Q3 FY19 was at Rs 1,242 crore with resulting net profit margin at 16.2 percent. Net profit for the third quarter last year was adversely impacted by one-time deferred tax adjustment of Rs 513 crore related to changes in US tax rates. Adjusted for this, net profit growth for Q3 FY19 was 49 percent year-on-year,” the company said. Consolidated revenue from operations of the company stood at Rs 7,740.19 crore for the quarter under consideration as against Rs 6,653.23 crore for the same period a year ago. Shares of Sun Pharmaceutical Industries were trading at Rs 440.50 per scrip on BSE, up 0.86 percent from its previous close.

Tags
NewsTracker SEBI Dilip Shanghvi
End of Article
Latest News
Find us on YouTube
Subscribe
End of Article

Impact Shorts

Tata Harrier EV vs Mahindra XEV 9e: Design and road presence compared

Tata Harrier EV vs Mahindra XEV 9e: Design and road presence compared

The Tata Harrier EV and Mahindra XEV 9e are new electric SUVs in India. The Harrier EV has a modern, familiar design, while the XEV 9e features a bold, striking look. They cater to different preferences: the Harrier EV for subtle elegance and the XEV 9e for expressive ruggedness.

More Impact Shorts

Top Stories

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Who is CP Radhakrishnan, India's next vice-president?

Who is CP Radhakrishnan, India's next vice-president?

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Israel targets top Hamas leaders in Doha; Qatar, Iran condemn strike as violation of sovereignty

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Nepal: Oli to continue until new PM is sworn in, nation on edge as all branches of govt torched

Who is CP Radhakrishnan, India's next vice-president?

Who is CP Radhakrishnan, India's next vice-president?

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Israel informed US ahead of strikes on Hamas leaders in Doha, says White House

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV